Haemophilus Influenzae Type b Vaccine

Drug #1628

Haemophilus Influenzae Type b Vaccine is a liquid or freez dried preparation of a polysaccharide, polyribosylribitol phosphate (PRP), derived from a suitable strain of Haemophilus influenza type b, covalently bound to a carrier protein. The immunogenicity, especially in young children, has been shown to be improved by linking the polysaccharides to a protein carrier such as diphtheria toxin or tetanus toxoid to form a conjugate vaccine. for active immunisation against Haemophilus influenzaetype b infections, among the major causes of meningitis and other esvere systemic illness in young children.

← Previous drug Next drug →

Primary Characteristics

It is of Semi Synthetic origin.

Non-proprietary name: Haemophilus Influenzae Type b Vaccine.

Molecular structure of Haemophilus Influenzae Type b Vaccine

Pharmacokinetics

None recorded.

Indications

Haemophilus Influenzae Type b Vaccine is primarily indicated in conditions like Haemophilus influenza type b infection.

Contraindications

Haemophilus Influenzae Type b Vaccine is contraindicated in conditions like Hypersensitivity, Severe febrile illness.

Dosage

None recorded.

Drug Interactions

None recorded.

Side Effects

Haemophilus Influenzae Type b Vaccine in overdosage may give rise to further complications which include Allergic reactions .

Haemophilus Influenzae Type b Vaccine produces potentially life-threatening effects which include Anaphylactoid reactions . Careful monitoring is needed with proper medical management.

Haemophilus Influenzae Type b Vaccine is known to cause more or less tolerable side effects which are usually transient. These include Diarrhea, Fever, Loss of appetite, Pain at injection site, Redness, Restlessness, Swelling at injection site, Unusual crying, Vomiting .

Warnings / Precautions

It should be used with caution in patients with a history of haemophilus influenza type b hypersensitivity, tetanus toxoid hypersensitivity, Neisseria meningitidis hypersensitivity or diphtheria toxoid hypersensitivity because antigens related to these products are used in haemophilus influenza vaccine. Vaccination with haemophilus influenza type b alone does not substitute for routine tetanus vaccination. Antigen detection does not have a diagnostic value in suspected Hib disease within 1-2 weeks of vaccination. Medical care must be available in case of rare anaphylactic reactions. In subjects who have received human gammaglobulins or a blood transfusion vaccination should be delayed for atleast three months .Different injectable vaccine should be administered at different injection site.

Available Brands

Click on a strength to view available brands.

Single Ingredient

Inj

10 mcg/dose

Multi-Ingredient Combinations

Inj

10 mcg

Drug Classification

1.19.3.1 — Vaccines for universal immunization

Manufacturers

Manufacturers of Haemophilus Influenzae Type b Vaccine in Pakistan:

GSK Hakimsons